Home / Peptides / Tesamorelin: One Approved Use, and What It Doesn't Cover
Tesamorelin: One Approved Use, and What It Doesn't Cover
Tesamorelin (Egrifta) is FDA-approved to reduce abdominal fat in adults with HIV and lipodystrophy only. What the trials show, risks and what isn't proven.
On this page
Quick facts
Fact sheet
- U.S. status
- Strongest evidence
- Human trials
- Status verified
Tesamorelin is the clearest example of a peptide that is FDA-approved and still easy to misdescribe. It is approved for one narrow use, its label rules out weight loss, and its main result is fat measured by imaging.
Key takeaways
- Tesamorelin is FDA-approved as Egrifta for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. Nothing else.
- Its label says it is not indicated for weight loss management, because it has a “weight neutral” effect.
- The main trial result is visceral fat measured by imaging, which is the basis of its approved use. Fat fell without body weight changing.
- The fat comes back when treatment stops. In the trials, visceral fat rose again after people switched to placebo.
- The label lists real risks with numbers, including elevated IGF-1, higher HbA1c, antibodies to the drug and injection-site reactions. Long-term cardiovascular safety has not been established.
- We found no evidence that it improves strength, slows aging or improves performance. It is on WADA’s Prohibited List.
What is tesamorelin approved for?
Egrifta WR and Egrifta SV (the brand names are used here only to identify the labels) are indicated for the “reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy” (Egrifta WR label, rev. 03/2025; Egrifta SV label, rev. 03/2024). It was originally approved on Nov. 10, 2010 (Drugs@FDA), and FDA now records the application as a biologics license application (BLA).
What the label says it is not for or does not establish:
- Not for weight loss. It is “not indicated for weight loss management as it has a weight neutral effect.”
- Cardiovascular safety: the long-term cardiovascular safety “has not been established.”
- No data supporting better HIV treatment adherence, no information in people over 65, and safety not established in children.
- Two formulations. Egrifta WR and Egrifta SV have different strengths and dosing. Dosing is set by each label and your prescriber; this guide does not give doses.
What did the trials show?
The approval rests on two multicenter phase 3 trials in adults with HIV and excess abdominal fat. Both were randomized 2 to 1, double-blind and placebo-controlled, and measured visceral fat (the fat deep in the abdomen) by CT scan at 26 weeks.
| Source | People | Visceral fat at 26 weeks |
|---|---|---|
| Label, study 1 | 412 | −18% vs +2%; difference −20% (95% CI −24 to −15). Body weight no different |
| Label, study 2 | 404 | −14% vs −2%; difference −12% (−16 to −7). Body weight no different |
| Falutz 2007, NEJM, study 1 | 412 | −15.2% vs +5.0%; triglycerides fell 50 mg/dl vs rose 9 |
| Falutz 2010, JAIDS, study 2 | 404 | −10.9% vs −0.6% |
| Falutz 2010, JCEM, pooled | 806 | −24 vs +2 cm²; effect −15.4%. Subcutaneous fat no significant change; better body image |
The figures differ between the label and the papers. The label uses an intent-to-treat analysis with the last observation carried forward. We did not check each paper’s method, so we cite each figure with its source and don’t mix them.
What the imaging result means. Visceral fat measured by CT is the basis of the approved use. These are phase 3 trials in people with HIV, and the result is a change in a scan measurement. The label does not claim that it lowers body weight, improves cardiovascular outcomes or improves HIV treatment.
What happens when people stop?
In the extension, visceral fat rose again in people switched to placebo and stayed lower in people who continued (label; Falutz 2008). Among people who continued, the reduction held at about −18% at 52 weeks. We found no durable effect after stopping.
Does it build muscle?
Not in a way that shows more strength or function. In the label’s trials, lean body mass rose about 1.2 to 1.3 kg at 26 weeks vs a small fall on placebo (−0.2 and −0.03 kg). An exploratory analysis found more trunk muscle density and area on CT at 26 weeks, comparing placebo only with people whose visceral fat fell by at least 8%. None of this measures strength or function, and lean mass is not the same as muscle. See our muscle growth guide.
What about uses beyond HIV?
None of these is an approved use, and most are small. We read these through their abstracts.
| Study | Design | People | Result | Limit |
|---|---|---|---|---|
| Stanley 2014, JAMA | Randomized | 50 with HIV and abdominal fat | Visceral fat difference −42 cm²; liver fat difference −2.9% | The authors call it preliminary |
| Stanley 2019, Lancet HIV | Randomized | 61 with HIV and fatty liver | Liver fat −4.1 points (95% CI −7.6 to −0.7) | Long-term effect to be determined; not an approved use |
| Russo 2024, AIDS | Analysis of that trial | 38 with HIV on integrase inhibitors; 31 finished | Less visceral and liver fat | Small |
| Makimura 2012, JCEM | Randomized | 60 without HIV: abdominal obesity with reduced growth hormone | Visceral fat difference −35 cm²; carotid thickness −0.04 mm; triglycerides −37 mg/dl | Markers, in a selected group |
| Baker 2012, Arch Neurol | Randomized | 152 older adults, healthy or with mild cognitive impairment | Favorable effect on cognition (intention-to-treat P=0.03) at 20 weeks; mild adverse events in 68% vs 36% | We reviewed no replication |
| Ellis 2025, JID | Open-label randomized | 73 with HIV and neurocognitive impairment | No significant difference in cognition (P=0.673) | Low power |
So the cognition evidence is one favorable and one neutral trial, and neither supports a claim that tesamorelin improves memory.
What are the risks?
From the Egrifta WR label. There is no boxed warning.
| Risk | What the label says |
|---|---|
| Contraindicated | Disruption of the hypothalamic-pituitary axis, active cancer, hypersensitivity, pregnancy |
| Cancer | It increases growth hormone, a growth factor. Weigh the higher baseline risk in HIV; any past cancer should be inactive and treated first; stop if there is evidence of recurrence |
| Elevated IGF-1 | Long-term effects unknown. At 26 weeks, 47% had an IGF-1 standard deviation score above 2 and 36% above 3 |
| Fluid retention | Swelling, joint pain, carpal tunnel syndrome |
| Blood sugar | HbA1c of 6.5% or higher in 5% vs 1% on placebo; the label gives a ratio of 3.3 (CI 1.4–9.6) |
| Hypersensitivity | 4%, with itching, redness, flushing, hives or rash |
| Injection sites | 25% vs 14% in the label’s warnings section |
| Antibodies | Anti-tesamorelin IgG antibodies in 50% at 26 weeks and 47% at 52; 85% among people who had hypersensitivity |
| Critical illness | Higher mortality with pharmacologic growth hormone in acute critical illness; consider stopping |
| Most common (over 5%) | Joint pain, injection-site redness and itching, pain in the limbs, peripheral edema, muscle pain |
Blood sugar: two readings. The pooled paper concluded there were no clinically meaningful changes in glucose parameters; the label reports the HbA1c difference above. For risk, we use the label.
How does tesamorelin differ from other peptides sold for fat loss or performance?
- It is approved; most of those are not. Tesamorelin’s benefits and risks were reviewed by FDA for one use. That is not true of peptides that are sold online for muscle or fat loss.
- It is regulated as a biological product (a BLA, per Drugs@FDA).
- It is not one of the six peptides in HHS’s Oct. 30, 2026 interim policy (HHS policy).
- Compounded versions are not FDA-approved. FDA does not review compounded drugs to evaluate their safety, effectiveness or quality before they reach patients. FDA’s 2020 notice says biological products that moved to licensure that year, a list that includes tesamorelin, are not eligible for the 503A and 503B compounding exemptions. We draw no legal conclusion about any product. A compounded product is not the same as Egrifta.
- Gray-market products. FDA cited tesamorelin products in warning letters dated Aug. 24, 2026, including a blend with ipamorelin (FDA letter). Mixes are not what was tested in the trials, and we do not link to or recommend sellers.
- Anti-doping. WADA’s 2026 Prohibited List names tesamorelin in class S2 (WADA).
Which claims are not supported?
- “FDA-approved for belly fat.” It is approved for excess abdominal fat in adults with HIV and lipodystrophy.
- “It helps you lose weight.” The label says it is not indicated for weight loss management.
- “It builds muscle.” Lean mass rose a little in the trials, and we found no strength data.
- “The fat loss lasts.” Visceral fat returned when treatment stopped.
- “It improves memory” or “slows aging.” One favorable and one neutral trial in different groups; no approval.
- “Any tesamorelin product is FDA-approved.” Only the Egrifta labeled uses are.
What should you ask your doctor?
- Is excess abdominal fat in my situation related to HIV and lipodystrophy, and what are the options?
- What would we track (visceral fat, IGF-1, blood sugar), and what happens when we stop?
- Do I have a history of cancer, a pituitary condition or a risk of pregnancy? (They are on the label’s contraindications or warnings.)
- Which product am I being prescribed: Egrifta WR, Egrifta SV or something else? Who makes it?
We do not give doses, cycles or preparation instructions, and we do not recommend sellers.
Frequently asked questions
Is tesamorelin FDA-approved?
Yes, as Egrifta, for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy.
Does tesamorelin help with weight loss?
No. Its label says it is not indicated for weight loss management. See our weight loss guide.
Does the fat come back?
In the trials, visceral fat rose again after people stopped.
Can athletes use tesamorelin?
It is on WADA’s Prohibited List. Athletes should check with their anti-doping organization.
Is compounded tesamorelin the same as Egrifta?
No. A compounded product is not an approved drug and has not been reviewed for safety, effectiveness or quality.
Sources we checked
- Egrifta WR prescribing information (DailyMed, rev. 03/2025)FDA. Accessed .
- Egrifta SV prescribing information (DailyMed, rev. 03/2024)FDA. Accessed .
- Drugs@FDA: BLA 022505 (Egrifta)FDA. Accessed .
- Falutz 2007: tesamorelin in HIV lipodystrophy, NEJM (PubMed)PubMed. Accessed .
- Falutz 2010: tesamorelin, second phase 3 trial, JAIDS (PubMed)PubMed. Accessed .
- Falutz 2010: pooled phase 3 trials, JCEM (PubMed)PubMed. Accessed .
- Falutz 2008: tesamorelin extension (PubMed)PubMed. Accessed .
- Adrian 2019: tesamorelin and muscle, exploratory analysis (PubMed)PubMed. Accessed .
- Stanley 2014: tesamorelin in HIV with abdominal fat, JAMA (PubMed)PubMed. Accessed .
- Stanley 2019: tesamorelin in HIV with fatty liver, Lancet HIV (PubMed)PubMed. Accessed .
- Russo 2024: tesamorelin in HIV on integrase inhibitors, AIDS (PubMed)PubMed. Accessed .
- Makimura 2012: tesamorelin in abdominal obesity with reduced GH, JCEM (PubMed)PubMed. Accessed .
- Baker 2012: tesamorelin and cognition, Archives of Neurology (PubMed)PubMed. Accessed .
- Ellis 2025: tesamorelin in HIV-associated neurocognitive impairment, JID (PubMed)PubMed. Accessed .
- HHS: Enforcement Discretion Policy, with Appendices A and BOther. Accessed .
- FDA warning letter, Aug. 24, 2026 (peptide products citing tesamorelin)FDA. Accessed .
- FDA: compounding laws and policiesFDA. Accessed .
- WADA 2026 Prohibited ListOther. Accessed .
- FDA: notice to compounders on changes that affect compounding, March 23, 2020FDA. Accessed .
- FDA: list of products transitioning to biologics licensesFDA. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.